Knight Therapeutics Inc.
Knight Therapeutics Inc.
- Market cap
- $1.09B
- P/E ratio
- 71.31
Your view on GUD.TO
Overview
What the company does, where it operates, and who runs it.
About Knight Therapeutics Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Samira Sakhia BCom, CA, CPA, MBA
- Headquarters
- 3400 De Maisonneuve Boulevard West, Montreal, QC, CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Samira Sakhia BCom, CA, CPA, MBA
- Headquarters
- 3400 De Maisonneuve Boulevard West, Montreal, QC, CA
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally.
It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma.
The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation.
In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections.
Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Knight Therapeutics Inc. from FRC's valuation model, read against the market price. GUD.TO last traded at C$11.14, 71.3× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Knight Therapeutics Inc.. Starting points for Knight Therapeutics Inc.: P/E 71.3, EPS C$0.16, beta 0.05 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Knight Therapeutics Inc.. Trailing twelve-month EPS for Knight Therapeutics Inc. stands at C$0.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Knight Therapeutics Inc.. Knight Therapeutics Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| BP8.AXBPH Global Ltd | Healthcare | ASX | — | ||
| BSPKBespoke Extracts, Inc. | Healthcare | OTC | $2.8M | ||
| BSPMBiostar Pharmaceuticals, Inc. | Healthcare | OTC | $264 | ||
| BUDZWEED, Inc. | Healthcare | OTC | $4.4M | ||
| CAAOFINDVR Brands Inc. | Healthcare | OTC | $3,025 | ||
| CABRCaring Brands, Inc. | Healthcare | NASDAQ | $6.0M | ||
| CAN.AXCann Group Limited | Healthcare | ASX | — | ||
| CANNTrees Corporation | Healthcare | OTC | $4.1M | ||
| CANQFCanaQuest Medical Corp. | Healthcare | OTC | $6.6M | ||
| CATV4Cable TV International, Inc. | Healthcare | OTC | $865,619 | ||
| CBDDCBD of Denver Inc. | Healthcare | OTC | $980,918 | ||
| CBDHFHempfusion Wellness Inc. | Healthcare | OTC | $1,635 | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Knight Therapeutics Inc.. Coverage tracks Knight Therapeutics Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Knight Therapeutics Inc.